Home / Market News / $SNDX
benzinga Corporate Catalyst Impact 85/100 ● negative

Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Oct 13, 2026, 12:02 PM UTC · Primary ticker $SNDX

Syndax Pharmaceuticals announced that its MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint, leading to a sharp decline in its stock. This news is a significant negative catalyst for Syndax, impacting its future drug development and market valuation.

Syndax Pharmaceuticals experienced a significant pre-market decline after its MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint. This is a critical setback for the company's drug pipeline and directly impacts its valuation, as clinical trial success is paramount for biotech firms. Other companies like BioNTech also saw declines due to clinical trial updates, and SentinelOne fell on news of a proposed convertible senior notes offering, which can dilute existing shares. While the overall market futures were mixed, these specific corporate catalysts drove individual stock movements, highlighting the importance of clinical trial outcomes and financing activities for investor sentiment. For traders, this signals a short-term bearish outlook for SNDX and potential volatility for BNTX and S.

$SNDX negative Phase 2 trial failure
$BNTX negative Clinical trial update
$S negative Proposed convertible senior notes offering
$ZBAO negative Continued decline
$CD negative Continued decline
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.